Formulation and Evaluation of Asenapine Maleate Loaded Niosomes for the Treatment of Schizophrenia
Keywords:
Schizophrenia, Asenapine maleate, Niosome, Quality by Design (QbD)Abstract
Niosomes are the non-ionic surface-active agent primarily based vesicles. The Key obstacle of Asenapine maleate have oral bioavailability (<2%) and extensive first pass effect. The objective key of the existing work was to formulate. Asenapine maleate loaded niosomes using quality by design and rectify it with some evaluation parameters to increase bioavailability, to lead better therapeutic effect and to minimize the side effects. Formulation of niosomes was done by three methods organic solvent injection method. Factorial design (32) experiments are significantly used to screen and to observe the effect of independent variables cholesterol and span 60 (X1, X2) on dependent variables particle size and entrapment efficiency (Y1, Y2). The results revealed optimized formulation ASP-niosome A2 amongst other formulations which was found lowest particle size 84 ± 5 nm and highest % EE 70 ± 2.0%. In-vitro drug release of optimized noisome was found 68 ± 1.20 % at the end of 8 hr and zeta potential was -17.53mV which stabilized the niosomal suspension. Characterization by SEM not only indicated the spherical shape of the niosomes but also confirmed the formation of vesicle. Locomotor activity was found to be significant in in-vivo pharmacodynamic study. Pharmacokinetic study carried out and it showed Cmax and t1/2 of 16.12ng/mL and 37.18 hr which is better than reported parameters for drug. Thus, concluded that Asenapine maleate loaded niosomes having effective anti-psychotic activity with increased bioavailability could be prepared successfully by organic solvent injection method using span 60 and cholesterol.
Downloads
References
Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2):127-35.
Lambert T. Selecting patients for long-acting novel antipsychotic therapy. Australas Psychiatry. 2006;14(1):38-42.
Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50(1):898-911.
Avachat AA, Kapure SS. Asenapine maleate in situ forming biodegradable implant: An approach to enhance bioavailability. Int J Pharm. 2014;477(1- 2):64-72. doi: http://dx.doi.org/10.1016/j.ijpharm.2014.10.006
Makeshwar K, Wasankar S. Niosomes: A novel drug delivery system. Asia J Pharma Research. 2013;3(1):16-20.
Bartelds R, Nematollahi MH, Pols T, Stuart MCA, Pardakhty A, Asadikaram G. Niosomes, an alternative for liposomal delivery. PLoS One. 2018;13(4):e0194179.
United States Food and Drug Administration, Press release. FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder. 2007. Available in: http:// www.fda.gov/News Events/News room/Press Announcements/ucm177401. htmL
Schering-Plough Corporation, Saphris (Asenapine) Sublingual Tablets US Prescribing Information. 519-520. Available in: http://www.spfiles.com/ pisaphrisv1.pdf
Vieta E. Asenapine: A new focus on the treatment of mania. Rev Psiquiatr Salud Ment. 2011;4(2):101-8.
Wiley VCH, Verlag GH, KGa A. Process Understanding: For Scale-up and Manufacture of Active Ingredients. Ian Houson. 2011;1:23-8.
Miksinski S. Regulatory Assessment of Applications Containing QbD Elements-Reviewer Experience. Am Ass Pharm Sci. 2012;1-34.
ICH: Q8 (R1). Pharmaceutical Development. Geneva, Switzerland. 2008.
Tan Q, Liu S, Chen X, et al. Design and Evaluation of a Novel Evodiamine- Phospholipid Complex for Improved Oral Bioavailability. AAPS Pharm Sci Tech. 2012;13(2):534-47. doi: 10.1208/s12249-012-9772-9
Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable Nanoparticles loaded with Insulin–Phospholipid Complex for Oral Delivery: Preparation, in vitro characterization and in vivo Evaluation. J Contr Rel. 2006;114(2):242-50. doi:10.1016/j.jconrel.2006.05.013
Avachat AA, Parpani SS. Formulation and development of bi-continuous nanostructured liquid crystalline particles of efavirenz. Colloids and Surface B: Biointerfaces. 2015;126(1):87-97. doi:10.1016/j.colsurfb.2014.12.014
Zhang J, Tang Q, Xu X, Li N. Development and Evaluation of a Novel Phytosome-loaded Chitosan Microsphere System for Curcumin Delivery. Int J Pharm. 2013;448(1):168-74. doi:10.1016/j.ijpharm.2013.03.021
Keservani R, Sharma A, Ayaz M. Novel Drug Delivery System for the Vesicular Delivery of Drug by the Niosomes. Int J Research Contr Release. 2011;1(1):1-8.
Chandu VP. Niosomes: A Novel Drug Delivery System. Int J Nov Trends Pharma Sci. 2012;2(1):25-31.
Madhav NVS, Saini A. Niosomes: A Novel drug delivery system. Int J Research Pharm Chem. 2011;1(3):498-511.
Andreson MJ, Whitcomb PJ. DOE Simplified: Practical Tools for Effective Experimentation, 2nded..,Taylor and Francis group, Boca Raton, New York. 2007;3:1-3.30.
Dumbare A, Shelke P, Gadhave M. Optimization: A Review. Int J Uni Pharm Life Sciences. 2012;2:2249-6793.
Mandlik S, Nandare D, Joshi M. Statistical optimization of or dispersible tablets containing Telmisartan using factorial design and response surface methodology. Res J Pharm Tech. 2009;2(3):548-51.
ElGamal SS, Naggar VF, Allam AN. Optimization of acyclovir oral tablets based on gastro retention technology: Factorial design analysis and physicochemical characterization studies. Drug Dev Indus Pharmacy. 2011;37(7):855-67.
Umah RS, Vignesh M. Formulation and evaluation of noisome containing Olanzapine. International Journal of Health and Pharmaceutical Sciences. 2011;1(3):100-12.
Guinedi A, Mortada N, Mansour S. Preparation and evaluation of reverse phase evaporation and multi lamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005;306(1-2):71-82.
Rani S, Hari V. Niosomal Formulation of Orlistat: Formulation and in-vitro
evaluation. Int J of Drug Dev Res. 2012;3(3):300-11.
Marston HM, Young JW, Geyer MA. Asenapine effects in animal models of psychosis and cognitive function. Psych Pharma. 2009;206(4):699-714.
Becker A. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003;27(4):687-700.
Moghaddam B, Adams B, Verma A. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921-7.
Duncan G, Moy S. Metabolic mapping of the rat brain after sub anesthetic doses of ketamine: Potential relevance to schizophrenia. Brain Res. 1998;787(2):181-90.
Duncan G, Leipzig J, Mailman R. Differential Effects of Clozapine and Haloperidol on Ketamine-Induced Brain Metabolic Activation. Brain Res. 1998;812(1-2):65-75.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
